Cadmium: Difference between revisions
(Created page with "Category:IEHIAS Category:Exposure Category:Biomarker :''The text on this page is taken from an equivalent page of the IEHIAS-project. Cadmium (Cd)...") |
mNo edit summary |
||
Line 67: | Line 67: | ||
Few comparative data exist about the geographical and temporal variations of Cd body burden in Europe. Although a decrease of the Cd body burden has been reported in the general population of some countries, human exposure shows little change compared to the drastic decrease of lead exposure. | Few comparative data exist about the geographical and temporal variations of Cd body burden in Europe. Although a decrease of the Cd body burden has been reported in the general population of some countries, human exposure shows little change compared to the drastic decrease of lead exposure. | ||
==See also== | |||
{{IEHIAS}} |
Latest revision as of 19:06, 25 September 2014
- The text on this page is taken from an equivalent page of the IEHIAS-project.
Cadmium (Cd), a by-product of zinc production, is a cumulative poison that can cause kidney and bone damage following prolonged exposure in the environment and the industry
Cadmium as a biomarker
Sample collection and storage
Matrix:
Blood and urine (untimed urine sample) are the biological samples commonly used to monitor exposure to Cd.
Kinetics:
- Inhalation is a main source of exposure in smokers and occupationally exposed persons. For others, food contributes to the majority of the intake
- Cadmium is mainly stored in the liver and kidneys, and is excreted via urine
- The biological half-life of Cd is about 100 days in blood and more than 10 years in urine
Sampling conditions:
Blood and urine should be collected in containers free of any metal contamination. Samples can be stored at 4°C or frozen.
Sample measurement
Analytical aspects:
- atomic absorption spectrometry (AAS) or inductively coupled plasma mass spectrometry (ICP-MS)
- Sensitivity in 0.01 to 0.1 µg/l
Performance characteristics:
- Analytical reproducibility is around 1-2 %
- Inter- and intralaboratory variability around 5-10%
Validation:
Various national and international intercomparison programs are in place, methods are well defined and a wide variety of certified standards and reference materials are available
Confounding factors:
Diuresis is a potential confounder of urinary Cd concentration. Smoking is a confounder for both blood and urinary Cd
Data interpretation
Concentrations reported in literature:
- Cd in blood of adult non-smoker: < 2 µg/l
- Cd in blood of adult smokers: < 5 µg/l
- Cd in blood of children: < 0.5 µg/l
- Cd in urine of adults: < 2 µg/g creatinin
- Cd in urine of children: < 0.5 µg/g creatinin
Dose-response/effect relationships:
Cd in blood (µg/l) or in urine (µg/g cr) | |
< 2 | Normal |
2-5 | Tubular proteinuria unlikely |
5-10 | Risk of tubular proteinuria in susceptible individuals |
> 10 | Dose-dependent increase in the risk of tubular proteinuria |
Time trend, geographical variation, susceptibel groups:
Few comparative data exist about the geographical and temporal variations of Cd body burden in Europe. Although a decrease of the Cd body burden has been reported in the general population of some countries, human exposure shows little change compared to the drastic decrease of lead exposure.